New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
08:50 EDTRPRXRepros Therapeutics weakness creates buying opportunity, says Roth Capital
After Repros' stock sold off yesterday, Roth Capital spoke with the company's management and is more confident that the outlook for the company's Androxal drug remains positive. The firm maintains a $19 price target and Buy rating on the stock.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
18:36 EDTRPRXOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTRPRXRepros Therapeutics: Results from Androxal study exhibit positive safety profile
Repros Therapeutics reported results from a large, controlled, long-term safety study comparing Androxal to a placebo. In this study of Androxal, ZA-303, no new safety signals were identified, including no evidence of negative effects on bone mineral density. Over 79% of the Androxal-treated subjects had morning testosterone levels above 300 ng/dL after being treated for 12 months. The last patient completed this study in late September. The Company's planned NDA will include study ZA-303, which will provide a significant portion of the support of long-term safety by providing data from 141 subjects exposed for one year or more. Over 200 subjects reached this milestone in the entire exposure database. ICH guidance for drugs to treat non-life-threatening conditions suggests that a minimum of 100 subjects should be exposed to the drug for one year.
October 17, 2014
09:17 EDTRPRXOn The Fly: Pre-market Movers
Subscribe for More Information
October 16, 2014
20:03 EDTRPRXRepros Therapeutics upcoming meeting with FDA to be Type C, not Type B
Subscribe for More Information
07:41 EDTRPRXRepros Therapeutics management to meet with Brean Capital
Subscribe for More Information
October 13, 2014
12:33 EDTRPRXOptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use